Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Shift Markets Launches New White Label Prediction Markets Platform

April 30, 2026

Analysis of the 2026 Oral Solid Dosage Contract Manufacturing Market – Scalable Pharma Solutions & Generic Demand Drive $59.05 Billion Forecast for 2030

April 30, 2026

Carrington College Launches Radiologic Technology Program at Temecula and Fresno Campuses

April 30, 2026

CFP® Professional Kathryn Berkenpas Appointed Chief Operating Officer of CFP Board

April 30, 2026

AITRADEBTC Announces Launch of AITRADEBTC Automated Cryptocurrency Trading Platform

April 30, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Generic Pharmaceuticals Contract Manufacturing Market Analysis Report 2026: $93.56 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Press Release

Generic Pharmaceuticals Contract Manufacturing Market Analysis Report 2026: $93.56 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

By News RoomApril 30, 20263 Mins Read
Generic Pharmaceuticals Contract Manufacturing Market Analysis Report 2026: .56 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, April 30, 2026 (GLOBE NEWSWIRE) — The “Generic Pharmaceuticals Contract Manufacturing Market Report 2026” has been added to ResearchAndMarkets.com’s offering.

The generic pharmaceuticals contract manufacturing market is experiencing robust growth. Projected to expand from $66.82 billion in 2025 to $71.65 billion in 2026, the market is set to continue ascending to an estimated $93.56 billion by 2030 at a CAGR of 6.9%. This growth is driven by increasing demand for generic drugs, the expansion of contract manufacturing organizations (CMOs), and a focus on advanced formulation technologies and biologics. The industry’s key trends include outsourcing for manufacturing, cost-effective production, and expansion into injectables and tablets, bolstered by improved regulatory compliance and licensing for generic products.

The rise of biosimilars is significantly directing the market’s trajectory. These affordable alternatives to costly biologic therapies enhance access to advanced treatments. Contract manufacturing supports the biosimilars sector with cost-efficient, large-scale production and regulatory expertise. According to Cardinal Health Inc., the U.S. witnessed an increase in FDA-approved biosimilars to 40 by 2023, highlighting the sector’s substantial growth potential.

Companies are establishing dedicated subsidiaries to meet the surging demand for contract manufacturing. For example, in 2025, Lupin launched Lupin Manufacturing Solutions (LMS) to specialize in contract development and manufacturing organization (CDMO) services, focusing on APIs. This strategic move positions them to provide high-quality contract manufacturing that emphasizes regulatory compliance and cost efficiency.

Additionally, Bora Pharmaceuticals acquired Upsher-Smith Laboratories for $210 million in April 2024, enhancing Bora’s capabilities across the pharmaceutical value chain. This acquisition broadens Bora’s reach from drug development to packaging and distribution.

Major players in the market include WuXi AppTec, Recipharm AB, Siegfried Holding AG, Curia Global Inc., and Piramal Pharma Solutions, among others. In 2025, North America led the market, with Asia-Pacific expected to be the fastest-growing region due to the shift in manufacturing norms and focus on local sourcing.

The market is adapting to tariff impacts on materials, encouraging local sourcing and domestic manufacturing investments to combat increased costs. This adaptation drives innovation in production processes, bolstering regional manufacturing capabilities.

Covering regions such as Asia-Pacific, North America, and Europe, the market report highlights growth opportunities, trends, and challenges. The generic pharmaceuticals contract manufacturing sector is poised for substantial expansion, driven by technological advancements and a shift toward biosimilars, underlining its critical role in global drug production.

Key Attributes:

Report Attribute Details
No. of Pages 250
Forecast Period 2026 – 2030
Estimated Market Value (USD) in 2026 $71.65 Billion
Forecasted Market Value (USD) by 2030 $93.56 Billion
Compound Annual Growth Rate 6.9%
Regions Covered Global


Report Scope:

  • By Drug Type:Branded Generics; Unbranded Generics
  • By Product Type:APIs; Formulations; Capsules; Tablets; Injectables
  • By Route Of Administration:Oral; Parenteral; Topical; Other Routes
  • By Application:Oncology; Immunology; Antidiabetic; Neurology; Anticoagulants; Cardiovascular; Respiratory; Pain; HIV Antivirals
  • By End-User Industry:Pharmaceutical Companies; CROs; Biotech Companies; Generic Drug Manufacturers

Companies Featured

  • WuXi AppTec Co. Ltd.
  • Recipharm AB
  • Siegfried Holding AG
  • Curia Global Inc.
  • Piramal Pharma Solutions
  • Laurus Labs Limited.
  • Cambrex Corp.
  • Alcami Corp. Inc
  • Neuland Laboratories Limited.

For more information about this report visit https://www.researchandmarkets.com/r/vuqg1z

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Generic Pharmaceuticals Contract Manufacturing Market

            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Shift Markets Launches New White Label Prediction Markets Platform

Analysis of the 2026 Oral Solid Dosage Contract Manufacturing Market – Scalable Pharma Solutions & Generic Demand Drive $59.05 Billion Forecast for 2030

Carrington College Launches Radiologic Technology Program at Temecula and Fresno Campuses

CFP® Professional Kathryn Berkenpas Appointed Chief Operating Officer of CFP Board

AITRADEBTC Announces Launch of AITRADEBTC Automated Cryptocurrency Trading Platform

HERNEST Launches FSC-Certified Teak Outdoor Collection

US Online Casino Real Money with High RTP Slots by SweepsPulse

Vereigen Media Wins Gold Stevie® Award at 2026 American Business Awards® for Redefining B2B Lead Quality Through Verified Engagement

Spring Into Gaming: HyperX Expands Its Gaming Peripherals and Software Ecosystem

Editors Picks

Analysis of the 2026 Oral Solid Dosage Contract Manufacturing Market – Scalable Pharma Solutions & Generic Demand Drive $59.05 Billion Forecast for 2030

April 30, 2026

Carrington College Launches Radiologic Technology Program at Temecula and Fresno Campuses

April 30, 2026

CFP® Professional Kathryn Berkenpas Appointed Chief Operating Officer of CFP Board

April 30, 2026

AITRADEBTC Announces Launch of AITRADEBTC Automated Cryptocurrency Trading Platform

April 30, 2026

Latest News

HERNEST Launches FSC-Certified Teak Outdoor Collection

April 30, 2026

Canadian manufacturing just saw largest monthly growth in 3 years: StatCan

April 30, 2026

US Online Casino Real Money with High RTP Slots by SweepsPulse

April 30, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version